Neurology · 2011 · 59 citations · 5 references
Life SciencesGeneticsNeurologyMedical GeneticsNeurodegenerationNeurogeneticsAmyotrophic Lateral SclerosisMolecular Basis Of NeurodegenerationMolecular NeurogeneticsNeurodegenerative Disease GeneticsNeurodegenerative DiseasesNeurodegenerative DisordersAmyotrophic Lateral Sclerosis PathologyPolyglutamine DiseasesPolyglutamine Expansion DisordersSporadic Amyotrophic Lateral Sclerosis
OBJECTIVE: Given the recent finding of an association between intermediate-length polyglutamine (polyQ) expansions in ataxin 2 and amyotrophic lateral sclerosis (ALS), we sought to determine whether expansions in other polyQ disease genes were associated with ALS. METHODS: We assessed the polyQ lengths of ataxin 1, ataxin 3, ataxin 6, ataxin 7, TBP, atrophin 1, and huntingtin in several hundred patients with sporadic ALS and healthy controls. RESULTS: Other than ataxin 2, we did not identify a significant association with the other polyQ genes and ALS. CONCLUSIONS: These data indicate that the effects of ataxin 2 polyQ expansions on ALS risk are likely to be rooted in the biology of ataxin 2 or ataxin 2-specific interactions, rather than the presence of an expanded polyQ repeat per se. These findings have important consequences for understanding the role of ataxin 2 in ALS pathogenesis and provide a framework for future mechanistic studies.
5
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS
Andrew C. Elden, Hyung Jun Kim, Michael P. Hart et al. · Nature · 2010 · 1.3K citations
Progressive Disruption of Cellular Protein Folding in Models of Polyglutamine Diseases
Tali Gidalevitz, Anat Ben‐Zvi, Kim H. Ho et al. · Science · 2006 · 651 citations
Androgen receptor gene polymorphisms in amyotrophic lateral sclerosis
O. Garofalo, Denise A. Figlewicz, P. Nigel Leigh et al. · Neuromuscular Disorders · 1993 · 21 citations